Filing Details

Accession Number:
0001209191-21-054286
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-01 17:23:31
Reporting Period:
2021-08-31
Accepted Time:
2021-09-01 17:23:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1342823 M Gregory Glenn C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
President, R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-08-31 53 $234.64 5,394 No 4 S Direct
Common Stock Disposition 2021-08-31 108 $237.14 5,286 No 4 S Direct
Common Stock Disposition 2021-08-31 320 $238.72 4,966 No 4 S Direct
Common Stock Disposition 2021-08-31 359 $239.66 4,607 No 4 S Direct
Common Stock Disposition 2021-08-31 175 $240.58 4,432 No 4 S Direct
Common Stock Disposition 2021-08-31 209 $241.59 4,223 No 4 S Direct
Common Stock Disposition 2021-08-31 100 $242.63 4,123 No 4 S Direct
Common Stock Disposition 2021-08-31 62 $244.03 4,061 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.51 to $235.00, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.65 to $237.44, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.08 to $239.00, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  5. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $239.12 to $239.90, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  6. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.18 to $241.10, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  7. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.22 to $242.04, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  8. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.29 to $243.02, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  9. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.83 to $244.22, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.